Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Operations: 2017-2024

Historic Cash from Operations for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to -$29.6 million.

  • Solid Biosciences' Cash from Operations fell 42.37% to -$29.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$100.0 million, marking a year-over-year decrease of 6.19%. This contributed to the annual value of -$100.0 million for FY2024, which is 6.19% down from last year.
  • As of Q4 2024, Solid Biosciences' Cash from Operations stood at -$29.6 million, which was down 25.04% from -$23.7 million recorded in Q3 2024.
  • In the past 5 years, Solid Biosciences' Cash from Operations ranged from a high of $1.3 million in Q4 2020 and a low of -$34.5 million during Q4 2022.
  • In the last 3 years, Solid Biosciences' Cash from Operations had a median value of -$24.4 million in 2024 and averaged -$24.3 million.
  • Per our database at Business Quant, Solid Biosciences' Cash from Operations soared by 106.15% in 2020 and then crashed by 1,697.09% in 2021.
  • Over the past 5 years, Solid Biosciences' Cash from Operations (Quarterly) stood at $1.3 million in 2020, then slumped by 1,697.09% to -$20.9 million in 2021, then tumbled by 65.18% to -$34.5 million in 2022, then surged by 39.61% to -$20.8 million in 2023, then plummeted by 42.37% to -$29.6 million in 2024.
  • Its Cash from Operations was -$29.6 million in Q4 2024, compared to -$23.7 million in Q3 2024 and -$21.5 million in Q2 2024.